(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Moderna's revenue in 2025 is $3,078,000,000.On average, 9 Wall Street analysts forecast MRNA's revenue for 2025 to be $747,817,907,310, with the lowest MRNA revenue forecast at $685,414,572,324, and the highest MRNA revenue forecast at $853,329,723,052. On average, 11 Wall Street analysts forecast MRNA's revenue for 2026 to be $978,182,304,436, with the lowest MRNA revenue forecast at $708,988,914,801, and the highest MRNA revenue forecast at $2,204,720,443,041.
In 2027, MRNA is forecast to generate $1,285,415,243,753 in revenue, with the lowest revenue forecast at $866,912,497,369 and the highest revenue forecast at $3,086,375,172,403.